Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Financing › Details

Rarity Bioscience–Novalis Biotech: investment, 202302 investment €0.5m by Novalis BIotech as extension of seed round now totalling €3m

 

Period Period 2023-02-06
  Predecessor Rarity Bioscience–SEVERAL: investment, 202211 seed financing round €2.5m led by founders + initial angel investors incl UU Invest
Organisation Money taker Rarity Bioscience AB
Products Product superRCA technology (for mutation detection from liquid biopsies)
  Product 2 venture capital
     

Novalis Biotech. (2/6/23). "Press Release: Novalis Biotech Invests in Rarity Bioscience’s Ultra Sensitive Genomics Technology". Uppsala.

To further accelerate growth, Rarity Bioscience announces today a new strategic investment from Belgium based Novalis Biotech. The investment is facilitated as an oversubscription of the recent round closed in November 2022. Apart from previous owner, that round also included Wallenberg Investments through Navigare Venture, now bringing the total investment round to €3M.

Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionise healthcare. The fund’s core competence lies in digitalization in the life sciences with a focus on “enabling technologies” within research and manufacturing technologies, genomics, bioinformatics, diagnostics, and personalised medicine. The Rarity superRCA technology is a new method for mutation detection from liquid biopsies, published in Nature Communications. The technology demonstrates superior sensitivity that enables earlier detection of cancer relapse, potentially leading to earlier treatment. Compared to competing methods, the superRCA assays are analyzed using existing lab instruments, which reduces both the costs and adoption barriers for labs.

Wim Van Criekinge, co-founder and Managing Director of Novalis commented “Rarity Bioscience impressed us with an exceptional team and pedigree of the founders. We share the company’s vision of deploying the elegant superRCA technology in emerging liquid biopsy applications across various oncology indications and beyond. We believe the combination of the technology’s unprecedented sensitivity and compatibility with widely available instrument infrastructure and workflows, will position the company to become a highly differentiated player in molecular diagnostics”

Linus Bosaeus, CEO of Rarity Bioscence added “Novalis came in late in the funding process, but I realized immediately that it was a very good fit. Working with Jaroslav Belotserkovsky and Wim Van Criekinge at Novalis during the late fall further confirmed that notion and I was very pleased when we landed the agreement to oversubscribe the round and bring them in at this stage. Novalis to me does not only have a great network and other interesting investments in the field, but also a deep scientific understanding and passion that holds a lot of value to us”


Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionise healthcare. The fund’s core competence lies in digitalization in the life
sciences with a focus on “enabling technologies” within research and manufacturing technologies, genomics, bioinformatics, diagnostics, and personalised medicine.


The Rarity superRCA technology is a new method for mutation detection from liquid biopsies, published in Nature Communications. The technology demonstrates superior sensitivity that
enables earlier detection of cancer relapse, potentially leading to earlier treatment. Compared to competing methods, the superRCA assays are analyzed using existing lab
instruments, which reduces both the costs and adoption barriers for labs.


Rarity Bioscience was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology, based on a discovery by Dr Lei
Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology. Rarity superRCA is an ultrasensitive
multiplex assay for detecting rare nucleic acid sequences in biological samples, enabling full potential of liquid biopsies and radically improving cancer diagnostics.

   
Record changed: 2023-08-03

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Rarity Bioscience AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top